September 14, 2011
12 Oversold Biotech Stocks Being Bought Up By Smart Money
by: Kapitall
SeekingAlpha.com
Analysts follow the buying trends of institutional investors such as hedge fund managers and mutual fund managers (a.k.a. the “smart money”) because these investors have greater access to sophisticated research than most investors. When a company sees increased buying from institutions, it’s a signal to take a second look.
We ran a screen on technically oversold stocks from the biotech industry, with RSI(14) below 40. We screened these stocks for those that have seen significant net institutional buying over the current quarter.
This is an interactive article, so if you're interested in biotechs, you need to go to the link below. However, the 12 are:
1. Amyris Biotechnologies Inc. (AMRS)
2. NPS Pharmaceuticals, Inc. (NPSP)
3. Insmed Incorporated (INSM)
4. Spectrum Pharmaceuticals, Inc. (SPPI)
5. Amicus Therapeutics, Inc. (FOLD)
6. Pacific Biosciences of California, Inc. (PACB)
7. 3SBio Inc. (SSRX)
8. Cadence Pharmaceuticals Inc. (CADX)
9. Codexis, Inc. (CDXS)
10. Sunesis Pharmaceuticals Inc. (SNSS)
11. Dendreon Corp. (DNDN)
12. Affymax, Inc. (AFFY)
http://seekingalpha.com/article/293515-12-oversold-biotech-stocks-being-bought-up-by-smart-money
Gold is $1,581/oz today. When it hits $2,000, it will be up 26.5%. Let's see how long that takes. - De 3/11/2013 - ANSWER: 7 Years, 5 Months
| 